Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma.
Rev Esp Med Nucl
; 29(1): 12-9, 2010.
Article
em En
| MEDLINE
| ID: mdl-20022140
ABSTRACT
We performed a retrospective study to evaluate the accuracy, diagnostic validity, and clinical impact of (18)F-FDG PET in the management of recurrent and metastatic disease in patients with Renal Cell Carcinoma (RCC) from our database. (18)F-FDG PET studies were identified from 58 patients that matched our criteria for inclusion in the study. Results were confirmed with histopathological findings, clinical follow-up time (at least 12 months), and/ or conventional imaging methods (CIM). A sensitivity of 80.56%, specificity 86.36%, diagnostic accuracy 58.7%, positive predictive value 90.63%, and a negative predictive value of 73.08% were observed. The clinical impact was high in 25 cases (43%) and we found no impact in only 10 studies (17.2%). We concluded that (18)F-FDG PET was useful and had a high clinical impact in the management of recurrent and metastatic RCC. From our data, it seemed that a positive PET study was more helpful to the physician than a negative study.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Radioisótopos de Flúor
/
Carcinoma de Células Renais
/
Compostos Radiofarmacêuticos
/
Fluordesoxiglucose F18
/
Tomografia por Emissão de Pósitrons
/
Neoplasias Renais
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Rev Esp Med Nucl
Assunto da revista:
MEDICINA NUCLEAR
Ano de publicação:
2010
Tipo de documento:
Article